In a filing, Kymera Therapeutics Inc revealed its Chief Legal Officer Chiniara Ellen unloaded Company’s shares for reported $68239.0 on Mar 03 ’25. In the deal valued at $30.45 per share,2,241 shares were sold. As a result of this transaction, Chiniara Ellen now holds 80,085 shares worth roughly $2.73 million.
Then, Chadwick Jeremy G sold 1,383 shares, generating $42,113 in total proceeds. Upon selling the shares at $30.45, the Chief Operating Officer now owns 67,800 shares.
Before that, Jacobs Bruce N. sold 7,035 shares. Kymera Therapeutics Inc shares valued at $214,219 were divested by the Chief Financial Officer at a price of $30.45 per share. As a result of the transaction, Jacobs Bruce N. now holds 201,886 shares, worth roughly $6.87 million.
Citigroup initiated its Kymera Therapeutics Inc [KYMR] rating to a Buy in a research note published on March 13, 2025; the price target was $52. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. BMO Capital Markets began covering KYMR with “Market perform” recommendation on December 06, 2024. Wells Fargo revised its rating on December 02, 2024. It rated KYMR as “an Overweight” which previously was an “an Equal weight”.
Price Performance Review of KYMR
On Tuesday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock fall -1.33% to $34.03. Over the last five days, the stock has gained 2.28%. Kymera Therapeutics Inc shares have fallen nearly -15.41% since the year began. Nevertheless, the stocks have fallen -13.87% over the past one year. While a 52-week high of $53.27 was reached on 01/27/25, a 52-week low of $29.07 was recorded on 03/04/25. SMA at 50 days reached $37.27, while 200 days put it at $41.50.
Levels Of Support And Resistance For KYMR Stock
The 24-hour chart illustrates a support level at 33.32, which if violated will result in even more drops to 32.60. On the upside, there is a resistance level at 34.58. A further resistance level may holdings at 35.12. The Relative Strength Index (RSI) on the 14-day chart is 46.90, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.63, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 22.98%. Stochastics %K at 74.69% indicates the stock is a holding.
How much short interest is there in Kymera Therapeutics Inc?
A steep rise in short interest was recorded in Kymera Therapeutics Inc stocks on 2025-02-28, dropping by -0.12 million shares to a total of 7.58 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 7.69 million shares. There was a decline of -1.52%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 18, 2024 when Stephens began covering the stock and recommended ‘”an Overweight”‘ rating along with a $65 price target.
